Accelovance, a full-service, global contract research organization (CRO), announces that Jeff Rudolph has joined as Chief Commercial Officer. He joins Accelovance from Chiltern, where he was vice president, Global Business Development. As CCO at Accelovance, Rudolph will oversee the global sales, marketing, and proposals groups to drive growth in market share and spearhead the integrated commercial success of the organization.
“Jeff is an outstanding addition to our executive team and will be instrumental in the continued growth of Accelovance,” said Steve Trevisan, CEO of Accelovance. “In my 30 years in this business I can say Jeff’s leadership and strategic thinking are second to none. His alignment with our focus on understanding our customer needs and delivering value in our relationships is a perfect fit, and I look forward to working with him in growing our global business.”
Rudolph brings 25 years of CRO and pharma/biotech industry experience including extensive global CRO team leadership experience. Rudolph is a seasoned planner and CRO business executive who knows how to deliver results in a "scale up" environment. During his time in the industry, he has worked with clients ranging from small biotech to large pharma, providing solutions that address their specific needs. In his role as vice president, Global Business Development at Chiltern, Rudolph was responsible for managing the global biotech sales team in North America, Europe and Asia Pacific.
Prior to Chiltern, Rudolph spent four years as one of five regional business development Executive Directors for ICON, and four years each in business development at PRA Health Sciences and SGS Life Sciences. Additionally, Rudolph spent four years as Global VP of Sales/Marketing for Healthcare Communications Group, and was employee number five when this organization was a startup (the company eventually sold after significant growth/expansion). His background encompasses extensive professional business experience growing pharma services companies from scratch to $100M/year in revenue.
Jeff holds a Master of Business Administration degree from the University of Texas and a B.S. in Biochemistry from the University of Missouri.